University of Pittsburgh researchers have developed a novel therapeutic vaccine that activates killer T cells to target HIV, offering new hope for treatment. The vaccine uses dendritic cells modified with specific molecules to stimulate the immune system's response.
Researchers found that multiracial congregations have dramatically different social ties compared to other Americans. Members in these congregations reported feeling accepted and having cross-racial friendships, which is lower than those in same-race or non-congregation groups.
Researchers found that B cells expressing a special protein called DC-SIGN are necessary for HIV to infect T cells. Activating DC-SIGN on B cells allows HIV to invade T cells, highlighting a new target for future studies and drug development.
The study found that the efavirenz plus two-NRTI regimen was significantly more effective at reducing HIV viral load in the blood. A second approach, lopinavir/ritonavir, also performed well and may be a viable alternative for patients who experience intolerable side effects from NRTIs. The trial included 753 participants and showed su...